Goldman Sachs
BBH icon

Goldman Sachs’s VanEck Biotech ETF BBH Stock Holding History

Goldman Sachs’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,800
Closed -$333K – 6764
2017
Q1 		$333K Buy
+2,800
New +$327K ﹤0.01% 5376

Other funds holding BBH

Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CCA
Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
PPWM
Paragon Private Wealth Management Lexington, Kentucky $383M AUM 36.18% 1-Year Est. Return

Goldman Sachs's BBH Position: Q2 2026 in Review

Goldman Sachs reduced its VanEck Biotech ETF (BBH) stake by 0.06% in Q2 2026, selling an estimated $11.1K and leaving 102,020 shares worth $20.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2591.

Goldman Sachs first reported a position in BBH in Q2 2013 and has held it in 45 quarters since. The position peaked at $162M in Q2 2015. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

  • Goldman Sachs held 102,020 shares of VanEck Biotech ETF worth $20.7M as of Q2 2026.
  • Goldman Sachs sold 59 VanEck Biotech ETF shares in Q2 2026, an estimated $11.1K.
  • VanEck Biotech ETF made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2591 holding.
  • Goldman Sachs first reported a position in VanEck Biotech ETF in Q2 2013 and has held it in 45 quarters since.
  • Goldman Sachs's VanEck Biotech ETF position peaked at $162M in Q2 2015.
  • 110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.